Progressive Retinal Toxicity Nine Years After Hydroxychloroquine Discontinuation: A Case Report

We report a case of hydroxychloroquine (HCQ) retinal toxicity showing continuous progression over nine years after cessation of HCQ. A 55-year-old female had a history of rheumatoid arthritis treated with HCQ 200 mg daily for 20 years (cumulative dose ≈1.46 kg). She had no previous retinal screening and was asymptomatic. She was referred in 2016 for the first time, and the drug was discontinued following detection of characteristic parafoveal retinal changes on spectral-domain optical coherence tomography and fundus autofluorescence consistent with HCQ toxicity. Despite discontinuation, serial imaging revealed ongoing progression of outer retinal and retinal pigment epithelium atrophy over nine years, with gradual enlargement of the parafoveal lesion and progression of the paracentral scotoma in both eyes. Best-corrected visual acuity remained stable in both eyes. This case highlights that retinal damage from HCQ may progress for many years after cessation, emphasizing the importance of early detection to reduce the risk of progression in this irreversible condition. Review post-cessation may identify those in whom further progression has occurred, who may benefit from practical support, such as visual aids and or assistive technology.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-12-07
DOI
https://doi.org/10.7759/cureus.98674
Citations
1
Primary Topic
Drug-Induced Ocular Toxicity
Type
article
Field-Weighted Citation Impact
1.71
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Progressive Retinal Toxicity Nine Years After Hydroxychloroquine Discontinuation: A Case Report

Christina Karakosta, Susan M. Downes
1 citations
Cureus
Drug-Induced Ocular Toxicity
1.71
article

Progressive Retinal Toxicity Nine Years After Hydroxychloroquine Discontinuation: A Case Report

Christina Karakosta, Susan M. Downes
article en
1 citations

Abstract

We report a case of hydroxychloroquine (HCQ) retinal toxicity showing continuous progression over nine years after cessation of HCQ. A 55-year-old female had a history of rheumatoid arthritis treated with HCQ 200 mg daily for 20 years (cumulative dose ≈1.46 kg). She had no previous retinal screening and was asymptomatic. She was referred in 2016 for the first time, and the drug was discontinued following detection of characteristic parafoveal retinal changes on spectral-domain optical coherence tomography and fundus autofluorescence consistent with HCQ toxicity. Despite discontinuation, serial imaging revealed ongoing progression of outer retinal and retinal pigment epithelium atrophy over nine years, with gradual enlargement of the parafoveal lesion and progression of the paracentral scotoma in both eyes. Best-corrected visual acuity remained stable in both eyes. This case highlights that retinal damage from HCQ may progress for many years after cessation, emphasizing the importance of early detection to reduce the risk of progression in this irreversible condition. Review post-cessation may identify those in whom further progression has occurred, who may benefit from practical support, such as visual aids and or assistive technology.

CureusVol. 17(12)
Nuffield Orthopaedic Centre (GB), University of Oxford (GB), Oxford University Hospitals NHS Trust (GB)
Openalex Percentile: Top 12%
Drug-Induced Ocular Toxicity
1.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.